Amgen releases 2022 Biosimilars Trends Report

Oct 12, 2022

Amgen published its 9th Biosimilars Trends Report, reporting on the current and future state of the US biosimilars market.  Among Amgen’s findings were the following:

  • Trends show an increase in savings per quarter, and in Q2 alone, savings in drug spend due to biosimilar availability are estimated to be $3.2 billion.
  • Biosimilars primarily covered under the medical benefit have typically launched at a wholesale acquisition cost (WAC) that is generally 10% to 57% lower than that of the reference product.
  • Seven or more launches of Humira® (adalimumab) biosimilars are possible in 2023. The entry of biosimilars is expected to lead to price declines across all products within the class.
Print Page Mail Article